Marc Beer is one of the founders and is the CEO of the biotech company Renovia. He has over 25 years of experience in the biotech and pharmaceutical development and was a member of the Mass Life Science Board of the Commonwealth of Massachusetts. Marc Beer also served as the Founding Chair and the Board of Genetics for the committee of Good Star Genetics. Marc Beer was also a strategic consultant for OvaScience, a biotech company that specializes in fertility treatment. OvaScience was founded in 2011 and headquartered in Waltham, Massachusetts. Learn more: https://www.slideshare.net/MarcBeer
Renovia was formed in 2016 by Marc Beer, Ramon Iglesias, and Yolanda Lorie. The company is focused on offering treatment for women’s pelvic disorders. It is headquartered in Boston, MA. The company has raised over forty million dollars for women’s health disorders. The money will go towards researching pelvic floor disorders such as urinary incognitance. Pelvic floor dysfunction can affect a wide range of organs and can occur when there is a muscle strain or tear. Damage to this region can occur during childbirth.
Beer wants to use the money that was invested in Renovia for research and development to help millions of women who are affected by pelvic disorders. He mentioned that his company plans to use sensor technology to utilize digital solutions to be able to further knowledge in this field and eventually lower healthcare cost for women who need treatment for pelvic floor disorders.
Renovia has been successful with some it’s early trials. In April 2018, it released a product called Leva that was approved by the FDA. Leva is used to monitor pelvic floor health and it provides exercises that can be used to strengthen this region. Leva is used as a way to offer a digital solution to manage health. It works well on an IOS system. Leva is only available for use if prescribed by a medical professional.
Along with Leva, Renovia is currently working on a new digital therapy program for pelvic floor programs called Reduce. The goal of this program is to improve and expand upon Leva and to help minimize symptoms of pelvic floor disorders.